Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

USD 21.53

(1.8%)

Total Assets Summary of Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd.'s latest annual total assets in 2023 was 513.21 Million USD , down -22.45% from previous year.
Biohaven Pharmaceutical Holding Company Ltd.'s latest quarterly total assets in 2024 Q1 was 418.53 Million USD , down -18.45% from previous quarter.
Biohaven Pharmaceutical Holding Company Ltd. reported annual total assets of 661.78 Million USD in 2022, up 365.84% from previous year.
Biohaven Pharmaceutical Holding Company Ltd. reported annual total assets of 142.06 Million USD in 2021, up 27.41% from previous year.
Biohaven Pharmaceutical Holding Company Ltd. reported quarterly total assets of 582.64 Million USD for 2024 Q2, up 39.21% from previous quarter.
Biohaven Pharmaceutical Holding Company Ltd. reported quarterly total assets of 618.52 Million USD for 2023 Q1, down -6.54% from previous quarter.

Annual Total Assets Chart of Biohaven Pharmaceutical Holding Company Ltd. (2023 - 2017)

Historical Annual Total Assets of Biohaven Pharmaceutical Holding Company Ltd. (2023 - 2017)

Year	Total Assets	Total Assets Growth
2023	513.21 Million USD	-22.45%
2022	661.78 Million USD	365.84%
2021	142.06 Million USD	27.41%
2020	111.49 Million USD	-67.61%
2019	344.26 Million USD	18.71%
2018	290.01 Million USD	97.44%
2017	146.88 Million USD	0.0%

Year	Total Assets	Total Assets Growth
2024 Q1	418.53 Million USD	-18.45%
2024 Q2	582.64 Million USD	39.21%
2023 Q1	618.52 Million USD	-6.54%
2023 Q2	506.73 Million USD	-18.07%
2023 Q3	382.73 Million USD	-24.47%
2023 FY	513.21 Million USD	-22.45%
2023 Q4	513.21 Million USD	34.09%
2022 Q4	661.78 Million USD	387.88%
2022 Q3	135.64 Million USD	-59.24%
2022 Q2	332.81 Million USD	-75.74%
2022 Q1	1.37 Billion USD	865.58%
2022 FY	661.78 Million USD	365.84%
2021 FY	142.06 Million USD	27.41%
2021 Q1	1 Billion USD	46.03%
2021 Q4	142.06 Million USD	-87.44%
2021 Q3	1.13 Billion USD	33.73%
2021 Q2	845.89 Million USD	-15.68%
2020 Q2	424.25 Million USD	-20.35%
2020 FY	111.49 Million USD	-67.61%
2020 Q3	782.01 Million USD	84.33%
2020 Q1	532.66 Million USD	54.73%
2020 Q4	686.97 Million USD	-12.15%
2019 Q2	490.9 Million USD	100.31%
2019 FY	344.26 Million USD	18.71%
2019 Q4	344.26 Million USD	-21.6%
2019 Q3	439.08 Million USD	-10.56%
2019 Q1	245.08 Million USD	-15.49%
2018 Q4	290.01 Million USD	48.65%
2018 Q2	239.29 Million USD	89.71%
2018 Q1	126.13 Million USD	0.0%
2018 FY	290.01 Million USD	97.44%
2018 Q3	195.09 Million USD	-18.47%
2017 Q1	60.19 Million USD	0.0%
2017 Q3	184.67 Million USD	-13.81%
2017 Q2	214.25 Million USD	255.96%
2017 FY	146.88 Million USD	0.0%
2017 Q4	- USD	-100.0%

Peer Total Assets Comparison of Biohaven Pharmaceutical Holding Company Ltd.

Name	Total Assets	Total Assets Difference
ADC Therapeutics SA	354.78 Million USD	-44.656%
Alto Neuroscience, Inc.	86.62 Million USD	-492.432%
Annovis Bio, Inc.	10.2 Million USD	-4927.417%
Ginkgo Bioworks Holdings, Inc.	1.66 Billion USD	69.183%
Nuvation Bio Inc.	621.48 Million USD	17.422%
Nuvation Bio Inc.	621.48 Million USD	17.422%
Arcus Biosciences, Inc.	1.09 Billion USD	53.131%
Zymeworks Inc.	580.88 Million USD	11.649%